Which NOAC is best for cutting stroke risk in AF and valvular heart disease?
Risks for ischaemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban in this setting, researchers say
For patients with AF and valvular heart disease, apixaban is associated with a reduced risk for ischaemic stroke or systemic embolism and a reduced risk for bleeding compared with rivaroxaban, according to a study published in the Annals of Internal Medicine.
Ghadeer K Dawwas (PhD), from the University of Pennsylvania in Philadelphia, and colleagues emulated a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and valvular heart disease (VHD) in a new-user cohort study.
